drugset / Trial / NCT04754815
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase II trial is to see how well single agent chemotherapy and pembrolizumab work elderly patients (≥ 75 years) with advanced non small cell lung cancer (NSCLC). Pembrolizumab stimulates your immune system to help fight lung cancer. This treatment approach may be better tolerated in elderly patients.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2025-04-01
- Completion
- 2026-04-01
Outcome
Outcome not reported
Stopped: “Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt to be clinically relevant.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg | Intravenous |